DDF

DDF is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the "faulty" nucleoside, resulting in apoptosis (cellular "suicide").
DDF is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types.

DDF - Pharmacology:

DDF inhibits thymidylate synthetase, leading to inhibition of DNA synthesis and cell death. DDF is a prodrug so activity occurs as a result of intracellular conversion to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate by deoxycitidine kinase. DDF diphosphate inhibits ribonucleotide reductase, the enzyme responsible for catalyzing synthesis of deoxynucleoside triphosphates required for DNA synthesis. DDF triphosphate (diflurorodeoxycytidine triphosphate) competes with endogenous deoxynucleoside triphosphates for incorporation into DNA.

DDF mini report

DDF OTC MONOGRAPH FINAL
OTC MONOGRAPH FINAL - A product marketed pursuant to a final OTC Drug Monograph
DDF TOPICAL
TOPICAL
DDF GEL
GEL
DDF LIQUID
LIQUID
DDF LOTION
LOTION
DDF HUMAN OTC DRUG
HUMAN OTC DRUG
Start - Stop data
START DATA:
2012-Jan-01
Start - Stop data
STOP DATA
2016-Oct-01

DDF for patients

General Patients receiving therapy with Gemzar should be monitored closely by a physician
experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and
do not need to result in discontinuation, although doses may need to be withheld or reduced.
There was a greater tendency in women, especially older women, not to proceed to the next
cycle.

Laboratory Tests Patients receiving Gemzar should be monitored prior to each dose with a
complete blood count (CBC), including differential and platelet count. Suspension or
modification of therapy should be considered when marrow suppression is detected.

DDF Interactions

No specific drug interaction studies have been conducted. For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.

DDF Contraindications

Gemzar is contraindicated in those patients with a known hypersensitivity to the drug (see Allergic under ADVERSE REACTIONS).

Generic name, Overdose, Half Life DDF, Food Interactions, Chemical, etc..

DDF see also FDA report

Brand Names containing Gemcitabine